Charles River investing in expanded biologics partnership with PathoQuest

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/Ca-ssis)
(Image: Getty/Ca-ssis)
Charles River Laboratories and PathoQuest have expanded their strategic partnership to help move vaccine, biologic, and gene-therapy candidates through the drug discovery and development pipeline.

“The expanded partnership with PathoQuest provides our biologics clients with access to PathoQuest’s next-generation sequencing (NGS) technology,”​ said Greg Beattie, ‎corporate vice president of global biologics testing solutions at ‎Charles River Laboratories.

PathoQuest’s technology combines a proprietary sample preparation method, equipment, and a curated pathogen database with a comprehensive BioIT analysis pipeline, Beattie explained.

The NGS solution is “a powerful test for identifying adventitious agents in a single, comprehensive analysis that minimizes false negatives while also providing a tool for the genetic characterization of cell lines,”​ he told us.

Charles River will also make a direct investment in PathoQuest as part of the expanded partnership.

“We are excited to offer our customers an industry-leading technology to help progress their vaccine, biologic and gene-therapy candidates through the drug discovery and development pipeline,”​ Beattie added.

“Working with PathoQuest, we are able to leverage our existing GLP and GMP capabilities with their NGS technology to offer a customized, fast, reliable and cost-effective solution.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us


View more